NKTR logo

NKTR
Nektar Therapeutics

8,800
Mkt Cap
$1.97B
Volume
348,655.00
52W High
$75.67
52W Low
$6.48
PE Ratio
-8.69
NKTR Fundamentals
Price
$68.87
Prev Close
$68.98
Open
$67.89
50D MA
$47.79
Beta
1.88
Avg. Volume
717,652.45
EPS (Annual)
-$8.68
P/B
15.93
Rev/Employee
$1.61M
$130.38
Loading...
Loading...
News
all
press releases
Erste Asset Management GmbH Takes $1 Million Position in Nektar Therapeutics $NKTR
Erste Asset Management GmbH purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the...
PR Newswire·4d ago
News Placeholder
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet
The mean of analysts' price targets for Nektar (NKTR) points to an 89.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·5d ago
News Placeholder
Nektar Therapeutics to Participate in Two Investor Conferences in March
Nektar Therapeutics to Participate in Two Investor Conferences in March Nektar Therapeutics to Participate in Two Investor Conferences in March PR Newswire SAN FRANCISCO, Feb. 24, 2026 SAN FRANCISCO...
PR Newswire·6d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week High - Time to Buy?
Nektar Therapeutics (NASDAQ:NKTR) Sets New 1-Year High - Should You Buy...
MarketBeat·6d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Given Buy Rating at B. Riley Financial
B. Riley Financial reiterated a "buy" rating and issued a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday...
MarketBeat·7d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $13,140.00 in Stock
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 180 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of...
MarketBeat·9d ago
News Placeholder
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 180 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at...
MarketBeat·10d ago
News Placeholder
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard Robin sold 423 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of...
MarketBeat·10d ago
News Placeholder
Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR
Persistent Asset Partners Ltd purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities...
MarketBeat·10d ago
<
1
2
...
>

Latest NKTR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.